Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 7/20 | 0.55 |
| ▸ | AXL | P30530 | 6/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.52 |
| ▸ | MET | P08581 | 3/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612199 | 0.90 | L3MBTL3 (0.59) | MERTKAXLL3MBTL3L3MBTL1PIK3CA | |
| SCHEMBL18612197 | 0.88 | MERTK (0.59) | MERTKAXLL3MBTL3L3MBTL1MET | |
| SCHEMBL21779417 | 0.85 | MERTK (0.64) | MERTKAXLL3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL18617156 | 0.83 | PIK3C3 (0.59) | MERTKAXLPIK3CAMTORMET | |
| SCHEMBL21779411 | 0.83 | AXL (0.60) | MERTKAXLL3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL10380840 | 0.83 | L3MBTL3 (0.59) | MERTKAXLL3MBTL3L3MBTL1MET | |
| SCHEMBL18615511 | 0.81 | BMPR1B (0.62) | MERTKAXLL3MBTL3L3MBTL1MET | |
| SCHEMBL18615821 | 0.80 | MERTK (0.58) | MERTKAXLL3MBTL3L3MBTL1MET | |
| SCHEMBL18580776 | 0.78 | MERTK (0.91) | MERTKAXL | |
| SCHEMBL18611887 | 0.77 | MERTK (0.59) | MERTKAXLL3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | disclosed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | MERTK 1/4885AXL 30/4885L3MBTL3 3333/4885 |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | MERTK 1/4885AXL 30/4885L3MBTL3 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.